Tirapazamine (TPZ,SR-4233, WIN 59075) is the first hypoxia-activated prodrug. Tirapazamine kills hypoxic cells by inducing chromosome aberrations and DNA double-strand breaks. Tirapazamine induced cell cycle arrest and apoptosis, and down-regulated HIF-1α, CA-IX and VEGF expression.
Tirapazamine (TPZ,SR-4233, WIN 59075) is the first hypoxia-activated prodrug. Tirapazamine kills hypoxic cells by inducing chromosome aberrations and DNA double-strand breaks. Tirapazamine induced cell cycle arrest and apoptosis, and down-regulated HIF-1α, CA-IX and VEGF expression.
Tirasemtiv (CK-2017357) is a a small-molecule fast-skeletal-troponin activator, which is being developed as a potential treatment for diseases and conditions associated with aging, muscle weakness and wasting or neuromuscular dysfunction.
Tirasemtiv (CK-2017357) is a a small-molecule fast-skeletal-troponin activator, which is being developed as a potential treatment for diseases and conditions associated with aging, muscle weakness and wasting or neuromuscular dysfunction.
Tirasemtiv (CK-2017357) is a a small-molecule fast-skeletal-troponin activator, which is being developed as a potential treatment for diseases and conditions associated with aging, muscle weakness and wasting or neuromuscular dysfunction.
Tirasemtiv (CK-2017357) is a a small-molecule fast-skeletal-troponin activator, which is being developed as a potential treatment for diseases and conditions associated with aging, muscle weakness and wasting or neuromuscular dysfunction.
Tirasemtiv (CK-2017357) is a a small-molecule fast-skeletal-troponin activator, which is being developed as a potential treatment for diseases and conditions associated with aging, muscle weakness and wasting or neuromuscular dysfunction.
Tiratricol (also known as TRIAC or triiodothyroacetic acid) is a thyroid hormone analogue.
Tirbanibulin (KX2-391) is a First-in-Class, highly selective non ATP-competitive Src inhibitor with GI50 of 9-60 nM in cancer cell lines .
Tirbanibulin (KX2-391) is a First-in-Class, highly selective non ATP-competitive Src inhibitor with GI50 of 9-60 nM in cancer cell lines .
Tirbanibulin (KX2-391) is a First-in-Class, highly selective non ATP-competitive Src inhibitor with GI50 of 9-60 nM in cancer cell lines .
Tirbanibulin (KX2-391) is a First-in-Class, highly selective non ATP-competitive Src inhibitor with GI50 of 9-60 nM in cancer cell lines .